CJC-1295 (No DAC)/IPAMORELIN BLEND (5mg/5mg)

This blend pairs CJC‑1295 (a growth‑hormone–releasing hormone analog) with Ipamorelin (a ghrelin‑receptor agonist). CJC‑1295 is investigated for promoting endogenous GH release via GHRH pathways, while Ipamorelin triggers GH pulses through GHSR‑1a with selective activity. Researchers often combine them to examine additive or synergistic effects on GH/IGF‑1 signaling, recovery markers, body‑composition parameters, and sleep quality indices. For laboratory research use only; not for human consumption.